Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company specializing in dermatology and photodynamic therapy (PDT). Its news flow centers on the commercialization and clinical development of Ameluz® and the RhodoLED® lamp series for the treatment of actinic keratoses and other skin conditions.
On this page, readers can follow company announcements related to financial results, such as quarterly and annual revenue updates, as well as business updates describing trends in Ameluz® sales and operating expenses. Biofrontera frequently reports on revenue performance, gross margin developments, and the impact of its strategic agreements on its financial profile.
News items also highlight clinical and regulatory milestones. These include database locks and completion of clinical studies in actinic keratosis on peripheral body areas, Phase 1 pharmacokinetics data, Phase 3 results in superficial basal cell carcinoma, and Phase 2 progress in acne vulgaris. The company uses press releases to describe how these data support supplemental New Drug Applications and future Phase 3 programs.
In addition, Biofrontera issues updates on strategic transactions and capital markets activity, such as the acquisition of all U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, changes to royalty and earnout structures, private placements of convertible preferred stock, and the divestiture of its Xepi® antibiotic cream license. Regulatory notices regarding Nasdaq listing compliance and participation in investor conferences are also part of the company’s regular news flow.
Investors and observers who want to track developments in dermatologic photodynamic therapy, label expansion efforts for Ameluz®-PDT, and Biofrontera’s financial and strategic progress can use this news feed as a centralized source of company-issued updates.
Biofrontera Inc. (Nasdaq: BFRI) announced the USPTO's notice of allowance for patent application No. 12/520,759, related to a novel nanoemulsion formulation. This patent covers compositions improving stability and cell penetration for dermatological treatments, enhancing the efficacy of Ameluz®. The company has also received a special designation for expedited review of a patent on novel photodynamic therapy (PDT) illumination protocols, further reinforcing its market position. This positions Biofrontera to broaden its offerings in dermatological treatments.
Biofrontera Inc. (Nasdaq: BFRI) announced that Leslie Hopkins, Associate Director of Marketing, was named a Trailblazer Brand Champion in Dermatology by PM360. The company’s Ameluz® campaign also earned nominations for “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year.” This recognition highlights the innovative marketing efforts led by Hopkins in raising awareness of photodynamic therapy for actinic keratosis. The PM360 awards ceremony will take place on September 22 in New York City.
Biofrontera Inc. (Nasdaq: BFRI) reported Q2 2022 revenues of $4.5 million, down 24% year-over-year, while total revenues for H1 2022 reached $14.2 million, up 34%. The company raised $8.7 million through a private placement and an additional $4.3 million post-quarter from warrant exercises. Operating expenses increased to $10.7 million in Q2, leading to a net loss of $0.9 million. Cash and equivalents stood at $31.9 million as of June 30, 2022. The company maintains its 2022 revenue guidance, projecting at least a 30% increase over 2021.
Biofrontera Inc. (Nasdaq: BFRI) announced it will report its financial results for the second quarter ended June 30, 2022, before the U.S. markets open on August 12, 2022. A conference call is scheduled for the same day at 11:00 a.m. Eastern time to discuss the results, provide a business update, and answer questions. The company's focus is on the commercialization of dermatological products, particularly for treating actinic keratoses and impetigo.
Biofrontera Inc. (Nasdaq: BFRI) announced a significant achievement with the Australian Patent Office granting a notice of allowance for their patent regarding innovative photodynamic therapy (PDT) protocols. This patent enhances the efficacy of Ameluz-PDT by combining reduced pain from daylight PDT with the effectiveness of conventional therapies. The innovation aims to improve treatment for skin diseases while minimizing patient discomfort. Hermann Luebbert emphasized the competitive advantage this patent offers, potentially leading to further protections of Ameluz in other regions, including the U.S.
Biofrontera (Nasdaq: BFRI) announced agreements with holders of existing warrants for 2,857,143 shares of common stock. The company has reduced the strike price from $5.25 to $1.62, prompting holders to exercise their warrants. Additionally, Biofrontera will issue new warrants for 4,285,715 shares at a strike price of $1.66, raising approximately $4.69 million. The company plans to file a registration statement within 30 days to register the resale of shares underlying the new warrants. This event is seen as a strategic move to bolster cash flow.
Biofrontera Inc. announced preliminary unaudited product revenues for Q2 and H1 2022, projecting revenues between $14.1 million and $14.3 million for the first half, a rise of 34% to 36% year-over-year and the highest in company history. However, Q2 revenues are expected to decrease by 21% to 25% compared to Q2 2021 due to a price increase implemented in April 2022. CEO Erica Monaco emphasized strong year-to-date performance and reaffirmed guidance for a 30% annual revenue growth. Final results are expected in August 2022.
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera (Nasdaq: BFRI) announced its participation in The Benchmark Healthcare House Call Virtual 1x1 Conference on June 2, 2022. Erica Monaco, CEO, and Hermann Lübbert, Executive Chairman, will engage with registered investors through virtual meetings and small group sessions.
Biofrontera is a biopharmaceutical company focused on dermatological products, including treatments for actinic keratoses and impetigo. For further information, visit biofrontera-us.com.
Biofrontera Inc. (Nasdaq: BFRI) highlights data from the American Cancer Society showing approximately 3.4 million U.S. residents may be diagnosed with non-melanoma skin cancer (NMSC) in 2022. This supports the commercial opportunity for Ameluz®, its flagship product. A recent market report forecasts the global NMSC market to grow by over $180 million with a CAGR of 5.8% until 2026. The company is focused on establishing Ameluz® as the leading PDT drug for actinic keratosis, with multiple ongoing clinical studies to expand its market potential.
FAQ
What is the current stock price of Biofrontera (BFRI)?
What is the market cap of Biofrontera (BFRI)?
